<DOC>
	<DOCNO>NCT00000707</DOCNO>
	<brief_summary>To confirm ability pulmonary ( lung ) function test ( PFT ) detect Pneumocystis carinii pneumonia ( PCP ) development clinical symptom determine pentamidine ( PEN ) , drug use treat PCP , give effectively aerosol ( inhaled mist ) . Other goal include measurement actual amount PEN reach lung , determine close clinical observation safer effective drug therapy prevention subsequent episodes PCP . Many AIDS patient develop PCP , effectiveness early diagnosis treatment PCP know . The effectiveness PEN may improve treatment begin parasite burden ( number organism lung ) still small , respiratory symptom appear . If PFT HIV-infected patient able identify patient early stage infection , outpatient treatment patient offer possible alternative expense toxicity continuous preventive therapy high-risk patient .</brief_summary>
	<brief_title>Aerosols Treatment Asymptomatic Pneumocystis Pneumonia : A Pilot Study Assessing Effectiveness Aerosolized Pentamidine Treatment Subclinical Pneumocystis Infection Patients With No Clinical Symptoms</brief_title>
	<detailed_description>Many AIDS patient develop PCP , effectiveness early diagnosis treatment PCP know . The effectiveness PEN may improve treatment begin parasite burden ( number organism lung ) still small , respiratory symptom appear . If PFT HIV-infected patient able identify patient early stage infection , outpatient treatment patient offer possible alternative expense toxicity continuous preventive therapy high-risk patient . Patients treat aerosolized PEN outpatient basis . The aerosol therapy give respiratory therapist 5 time week , total 21 day treatment . In addition , patient participate two radioactive aerosol study patient inhales radioactive gas sit his/her back gamma camera . The resulting picture outline lung . Then gas exhale patient breathes aerosol PEN . This mist contain single dose PEN mix small amount radioactivity ( 99mTc-pertechnetate ) . The gamma camera determine particle deposit lung . The radioactive exposure equivalent typical x-ray rib . Patients also undergo diagnostic bronchoscopy lavage , PFT . Blood drawn measure blood level PEN . Patients follow ( clinical exam PFT 's ) 6 month end therapy . Prophylaxis PCP allow 6-month follow-up .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Pneumocystis</mesh_term>
	<mesh_term>Pneumocystis Infections</mesh_term>
	<mesh_term>Pentamidine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Treatment : Allowed aerosolization : Metaproterenol albuterol treat bronchospasm . Patients must : HIV infection confirm ELISA , HIV culture , p24 antigenemia . Suspected subclinical Pneumocystis carinii infection detect &gt; 10 percent change lung volume and/or diffuse capacity indicative progressive restrictive disease detect monthly screen pulmonary function test ( PFT 's ) . Patients afebrile respiratory sign symptom clinical disease . Morphologic confirmation pneumocysts determine bronchoalveolar lavage ( BAL ) perform 24 hour initial aerosol inhalation . If BAL negative pneumocysts , patient withdrawn protocol follow per screen PFT protocol Stony Brook . Diagnostic bronchoscopy BAL must perform within 2 week detection &gt; 10 percent change PFTs . Ability willingness sign inform consent . Prior Medication : Allowed : Primary prophylaxis agent active Pneumocystis carinii pneumonia ( PCP ) , 5 patient may receive prior prophylaxis aerosolize pentamidine . Zidovudine . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : History Pneumocystis carinii pneumonia ( PCP ) . Development respiratory sign and/or symptom interval detection pulmonary function test ( PFT ) abnormality time initial aerosol deposition . Dyspnea , cough , bronchospasm prevents cooperation aerosol administration . History major adverse reaction pentamidine define absolute neutropenia , &lt; 750 polymorphonuclear leukocyte plus band ; thrombocytopenia , &lt; 40000 platelet ; creatinine rise , &gt; 3.0 mg/dl ; liver function abnormality , SGOT SGPT &gt; 5 x normal ; hypoglycemia , &lt; 50 mg/dl ; rash , exfoliative mucositis ; cough , unremitting cough bronchospasm uncontrolled bronchodilator prevent &gt; 50 percent dose deliver &gt; 2 day . Concurrent Medication : Excluded : Zidovudine . Patients unable cooperate aerosol administration exclude . Prior Medication : Excluded : Another antiprotozoal regimen episode . Unable complete therapy followup social reason opinion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Respiratory Function Tests</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Pneumonia , Pneumocystis carinii</keyword>
	<keyword>Pentamidine</keyword>
	<keyword>Lung</keyword>
	<keyword>HIV Seropositivity</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Administration , Inhalation</keyword>
	<keyword>Aerosols</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>